For the purpose of external validation, an external cohort consisting of 50 cases with R/R cHL who underwent anti‐PD‐1‐based immunotherapy for the first time during 2016–2024 at Department of Hematology in the Fifth Medical Center of the Chinese People's Liberation Army General Hospital was used. Here, PDCD1 is linked to classic Hodgkin lymphoma.